Showcases Stock ranks Forex

Vanda Pharmaceuticals (VNDA)
6.75  0.13 (1.96%) 03-24 16:00
Open: 6.59 Pre. Close: 6.62
High: 6.78 Low: 6.59
Volume: 400,515 Market Cap: 383(M)
Stock Technical Analysis
Target: Six months: 8.29
One year: 9.69
Support: Support1: 6.46
Support2: 6.06
Resistance: Resistance1: 7.10
Resistance2: 8.29
Pivot: 6.42
Moving Averages: MA(5): 6.65
MA(20): 6.42
MA(100): 8.13
MA(250): 9.51
MACD: MACD(12,26): -0.09
Signal(12,26,9): -0.18
%K %D: %K(14,3): 73.84
%D(3): 76.87
RSI: RSI(14): 54.59
52-Week: High: 12.34
Low: 6.06
Change(%): -40.7
Average Vol(K): 3-Month: 590
10-Days: 770
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 6.788 - 6.814 6.814 - 6.834
Low: 6.522 - 6.554 6.554 - 6.579
Close: 6.702 - 6.751 6.751 - 6.791
Price, MAs and Bollinger Bands
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.

[ VNDA ] has closed below upper band by 5.8%. Bollinger Bands are 50.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.
Company profile
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and VHX-896, the active metabolite of iloperidone. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Stock chart
Stock News
Fri, 24 Mar 2023
Corbus Pharmaceuticals Holdings Inc. stock rises Friday, outperforms market - MarketWatch

Fri, 17 Mar 2023
Is Vanda Pharmaceuticals Inc. (VNDA) Stock Worth a Buy Friday? - InvestorsObserver

Fri, 17 Mar 2023
Vanda Pharmaceuticals Appoints Dr. Tage Honoré to its Board of ... - PR Newswire

Thu, 16 Mar 2023
Corbus Pharmaceuticals Holdings Inc. stock rises Thursday, outperforms market - MarketWatch

Fri, 10 Mar 2023
Rockville biotech Shuttle Pharma inks deal to advance key drug ... - The Business Journals

Fri, 10 Mar 2023
Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors - MarketWatch

Financial Analysis
Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  NASDAQ Global Market
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 56.79
Shares Float (M) 52.12
% Held by Insiders 3.68
% Held by Institutions 100.47
Shares Short (K) 2430
Shares Short Prior Month (K) 2000
Stock Financials
EPS 0.110
Book Value (p.s.) 9.280
Profit Margin 2.47
Operating Margin 2.49
Return on Assets (ttm) 0.6
Return on Equity (ttm) 1.2
Qtrly Rev. Growth -5.2
Gross Profit (p.s.) 4.052
Sales Per Share 4.479
EBITDA (p.s.) 0.160
Qtrly Earnings Growth -0.60
Operating Cash Flow (M) 31.98
Levered Free Cash Flow (M) 32.34
Stock Valuation
PE Ratio 61.36
PEG Ratio 0.48
Price to Book value 0.73
Price to Sales 1.51
Price to Cash Flow 11.99
Stock Dividends
Dividend Yield
Dividend Growth

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android